CRP and stroke disorder: At a median follow-up of 3 years, the primary composite efficacy endpoint was not significantly different between treatment groups, despite a significant reduction in CRP levels in patients assigned to colchicine.39 Non-cardiovascular death was significantly lower in the colchicine group compared with the placebo group, though the reason for this difference remains unclear.39 All the other individual endpoints, including cardiovascular death, MI, and stroke, were not significantly different between treatment groups.39